Pilot testing with leading healthcare providers demonstrates increased patient engagement and operational efficiencies, fueling nationwide rollout
Philadelphia, PA, June 11, 2025—GLOBO Language Solutions, the leading B2B provider of interpreting and translation services, announced availability today of its artificial intelligence (AI) interpreter, GLOBO KAI™, making the app available to clinicians and healthcare staff at 3,000 U.S. health systems, hospitals, and physician practices nationwide.
KAI puts AI linguistic support at the fingertips of clinicians and administrative staff, facilitating greater coverage for the limited English proficiency (LEP) population across multiple touchpoints in their healthcare journey. Currently supporting more than 20 languages ‒ including Spanish, Arabic, Mandarin, Cantonese, and Portuguese-Brazilian ‒ with additional languages planned, KAI assures AI-powered, comprehensive language interpretation accessible through the GLOBO Connect App.
Based on 2025 pilot test results, GLOBO’s AI interpreter technology proved particularly effective in supporting communication gaps along the patient journey in non-clinical, administrative settings. At pilot site Affinia Healthcare, a Community Health Center (CHC) in St. Louis, Mo., KAI provided instant access, reducing wait times and helping to:
- Streamline intake and patient flow beyond the front desk
- Identify communication gaps across multiple encounters with ancillary services, and
- Support Health Resources and Services Administration (HRSA) compliance
We found that it was really beneficial for our front desk staff, who were previously struggling to efficiently connect patients with interpreters,” said Jennifer Winters, assistant vice president of Value Based Care at Affinia Healthcare. “With the AI interpreter app, we could direct patients through registration, pharmacy, and back to Convenient Care much faster.”
Financial game changer
From an economic standpoint, high-quality AI interpretation promises to be a financial game-changer, significantly reducing costs by streamlining LEP patient interactions and increasing points of language access across the patient journey. McKinsey & Company and Harvard researchers estimate that AI is expected to impact healthcare savings by 5-10%, or roughly $360 billion annually. Given that healthcare facilities incur roughly $279 per LEP patient per year, and the availability of certified resources is in seriously short supply, potential savings could be substantial.
Said GLOBO CEO Dipak Patel, “Reducing healthcare expenses is a national priority—especially for federally funded programs. New AI innovations like GLOBO KAI present a promising path forward to improve cost efficiency and sustainability, while vastly improving patient engagement and overall care.”
AI-powered interpreting fills in care gaps
When communication breakdowns arise with LEP patients, patient safety, care management, and health outcomes may be compromised. Numerous research studies report that language barriers between providers and LEP patients can lead to poorer outcomes and drive up the cost of care through increased readmissions, extended hospital stays, and preventable errors.
Despite widespread recognition of this challenge, some healthcare organizations and their language service providers struggle to consistently evaluate, improve, and expand the quality and reach of their medical interpreting services. Providing accurate, culturally appropriate, and linguistically sensitive interpretation at the onset of a limited-English-speaking patient’s care is key to equitable communication, bridging care gaps, and setting the stage for better outcomes.
GLOBO AI interpreter pilot program
GLOBO conducted its AI interpreter pilot program in early 2025 to test the effectiveness of its proprietary, healthcare-optimized AI interpreting technology at multiple provider settings. Participants included Affinia Healthcare, a large, not-for-profit healthcare system with 16 hospitals, multiple clinics, and other healthcare facilities across Illinois and Michigan, and a specialty hospital in Louisiana.
From January 1 to April 1, 2025, clinicians at the test sites conducted a series of calls with Spanish-speaking LEP patients to evaluate accuracy, receptivity, and improved clinician and patient satisfaction. Calls were evaluated to verify the LEP patient’s understanding and the overall quality of the auto-interpreting experience. Last month, Jenny Esno, GLOBO’s senior vice president of commercial, presented findings from a recent company study at ATA Nexus 2025, highlighting how mobile AI tools are reshaping clinician-patient communication, improving engagement, and reducing costs for LEP populations.
Summing up the pilot findings, Patel said, “AI interpretation is a proven, viable option to improve engagement across the LEP patient’s healthcare journey, especially in non-clinical, administrative applications. Our solution effectively demonstrated that mobile AI interpreting can help to reduce language barriers and improve patient-clinician relationships, especially when leveraging the full breadth of in-person, telephone, and video language solutions, ultimately lowering overall language solutions costs.”
About GLOBO
GLOBO Language Solutions (“GLOBO”), in Philadelphia, Pa., delivers on-demand interpreting and translation services powered by GLOBO HQ and GLOBO Connect, featuring AI technologies GLOBO Live Quality and GLOBO KAI™. The company manages an independent global network of 8,000+ linguists who speak more than 430 languages and dialects. GLOBO supports diverse industries including healthcare, government, education, and federal and state courts, with 24/7 audio, video, on-site, and sign language interpreting, and translation—all informed by actionable insights. GLOBO ranks No. 17 globally and No. 10 in the U.S. on Slator’s 2025 Language Service Provider Index and No. 35 on Nimdzi’s 2025 list of the 100 Largest Language Service Providers. The company was named to Modern Healthcare’s2025 Best Places to Work in Healthcare list, is an eight-time Inc. 5000 honoree, a 2024 Deloitte Technology Fast 500™ winner, and a 2024 Vendors Division Semi-Finalist in Healthcare Innovation’s Innovator Awards. Follow GLOBO on LinkedIn, X, Instagram, and Facebook.
